Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poliflav M.A. is a multi-ingredient vascular support formulation, typically classified as a dietary supplement or nutraceutical, primarily utilized in the management of chronic venous insufficiency and microcirculatory disorders. Its core composition includes a combination of bioflavonoids: diosmin, troxerutin, and hesperidin. The therapeutic effect is achieved through phlebotonic and vasoprotective actions. Diosmin increases venous tone by inhibiting catechol-O-methyltransferase (COMT), which leads to prolonged activity of norepinephrine on the venous wall. Troxerutin and hesperidin contribute by reducing capillary hyper-permeability and providing anti-inflammatory effects through the inhibition of pro-inflammatory mediators and the expression of adhesion molecules. The product is frequently indicated for conditions such as varicose veins, hemorrhoidal disease, and capillary fragility, and it is largely associated with the Italian pharmaceutical market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Poliflav M.A..